Keywords: Eli Lilly, Financial results Second-quarter 2012

Eli Lilly 2nd-qtr sales and earnings tumble on Zyprexa patent expiry, but still beat forecasts

Article | 26 July 2012

US drug major Eli Lilly (NYSE: LLY) reported that second-quarter 2012 worldwide revenue declined 10% to $5.6 billion, driven lower by schizophrenia drug ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Eli Lilly

Go to company listing